Learn more about our Legal work.
On September 13th, 2023, the U.S. House Oversight Committee held a hearing on the impact of third-party litigation financing, an issue of significant concern to AdvaMed and its members. Third-party…
Today, AdvaMed, the Medtech Association, submitted a letter to the House Committee on Oversight and Accountability regarding the Committee’s consideration of an issue that threatens to undermine the foundations of…
Register for the 16th Annual King & Spalding Medical Device Summit in Chicago!
AdvaMed submits amicus briefs on a variety of topics because of the strong interest and relevance to the medtech industry.
Chris White, AdvaMed’s General Counsel, explores the GAO’s recent report as “a welcome independent review raising attention to the need for disclosure and regulation of the litigation financing that fuels…
AdvaMed, the medtech association, recently commented on the FTC’s proposed rule that would ban employers from imposing or enforcing non-compete clauses in contracts with certain workers. AdvaMed opposes the FTC’s vastly…
The Federal Trade Commission published a proposed rule in the Federal Register that would, among other things, prohibit employers from imposing non-compete agreements on their employees.
AdvaMed, the medtech association, asked the Supreme Court to affirm the judgments of the court of appeals in the Seventh Circuit in a significant case concerning the False Claims Act…
AdvaMed’s medtech priorities for the 118th Congress highlight opportunities to address the most important issues facing patients and the medical technology industry today.
AdvaMed responded to HHS OIG’s annual solicitation of proposals for new and modified safe harbors and special fraud alerts.